Euthymics Bioscience, Inc. Presents Data That Support Advancing EB-1020 into Clinical Trials for Adult ADHD
12/7/2011 6:35:32 AM
CAMBRIDGE, Mass. & WAIKOLOA, Hawaii--(BUSINESS WIRE)--Euthymics Bioscience, Inc. today announced that it has presented preclinical data demonstrating that EB-1020, a next-generation product candidate for adult attention deficit/hyperactivity disorder (ADHD), may be effective for treating ADHD without the burden of drug abuse liability. Euthymics’ EB-1020 is a novel triple reuptake inhibitor formulated for the treatment of ADHD as a norepinephrine and dopamine-preferring triple, with a small effect on serotonin. This combines the pharmacology of the brain chemicals most relevant for the treatment of ADHD in a single molecule—norepinephrine is believed to help with focus, while the increased dopamine is believed to improve problem solving capabilities, and may also lead to a faster speed-of-onset. EB-1020 is also active in animal models of depression, a common co-morbidity of ADHD. The data were presented at the 50th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Hawaii.
comments powered by